Eckert & Ziegler BEBIG predicts loss for the financial year 2014 - 500 Beiträge pro Seite | Diskussion im Forum

[Nachrichten [wO]]

Seneffe, Belgium, January 5, 2015. Due to the ongoing economic and political crisis in Eastern Europe and unexpectedly difficult conditions in the Americas business, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB) was …

Lesen sie den ganzen Artikel: Eckert & Ziegler BEBIG predicts loss for the financial year 2014

[R-BgO]

bin mal gespannt, was das für die Mutter bedeutet...

[R-BgO]

historischer Thread: IBT - International Brachytherapie

[R-BgO]

Brachytherapy expansion of Argentinean Mevaterapia supported by Eckert & Ziegler BEBIG

Co-60 MultiSource® afterloader


Seneffe, Belgium, August 19, 2015,

Eckert & Ziegler BEBIG has installed its first MultiSource® afterloader in Argentina. The installation was carried out in the medical center Mevaterapia which is the radiotherapy department of the Hospital Italiano de Buenos Aires.

Mevaterapia is a full care radiotherapy center that offers CT, IMRT, superficial radiotherapy, CNS, total body irradiation, photon and electron therapy and LDR prostate brachytherapy. Dr. Federico Diaz, Deputy Medical Director and Radiotherapist at Mevaterapia states: "With MultiSource®, we plan to expand the yearly amount of gynecological brachytherapy treatments to 260 in 2015 and continuously more over the next years. In the near future, we also plan to offer dermatological as well as rectum, anus, sarcoma and especially breast brachytherapy to treat the cancer with the highest incidence among females in Argentina.

The decision to select cobalt-60 over iridium-192, although both isotope types are offered for all Eckert & Ziegler BEBIG afterloader types, was due in large part to time savings in performing quality assurance checks after each source exchange and in import logistics. Cobalt-60 has a longer half-life in comparison to iridium-192, lasting more than five years compared to only three month for iridium-192. Additionally, Dr. Diaz points out that the 3D treatment planning options together with the Eckert & Ziegler BEBIG CT and MR compatible applicators played a significant role in the decision for MultiSource® and the HDR treatment planning system SagiPlan®.

[R-BgO]

Eckert & Ziegler BEBIG installs first MultiSource® afterloader in Myanmar

Seneffe, Belgium, August 26, 2015,

Eckert & Ziegler BEBIG installed the first MultiSource® afterloader in Myanmar. The installation was done in the Mandalay General Hospital and is the first HDR afterloader in the country using cobalt-60.

The Radiotherapy Department of the Mandalay General Hospital has worked with manual brachytherapy in recent years and now started with HDR afterloading for gynecological cancers. The first treatments were already performed at the end of July after intense training sessions with Eckert & Ziegler BEBIG application specialists. Antonius Spiller, Senior Application Specialist with a record in radiation therapy of more than 25 years states: "Myanmar has an aspiring healthcare sector and healthcare professionals are eager to incorporate efficient and cost-effective equipment in the fight against cancer." In the Mandalay General Hospital, MultiSource® will have a significant impact on the treatment of cervical cancer which is the second most frequent cancer among women in the Southeast Asian country. Every year 5286 women are diagnosed with cervical cancer and 2998 die from the disease.

"Our training, which accompanied the installation of the Co-60 machine, included a complete range of tasks from the HDR brachytherapy process like source quality insurance, security and emergency procedures, use of applicators, software training on the treatment planning system HDRplusTM, set-up and testing of DICOM settings at the C-arm and CT. Application specialists were also present during the first treatments for assistance if necessary." explains Antonius Spiller.

Eckert & Ziegler BEBIG has a dedicated team of application specialists around the world who support customers from the installation to the end of life of our products. Our goal is to assist in all steps of the brachytherapy treatment process to ensure optimal system use. For more information, please contact your local Eckert & Ziegler BEBIG representative or write an e-mail to [e-mail].

[R-BgO]

Dr. Harald Hasselmann appointed as new managing director of Eckert & Ziegler BEBIG

Seneffe, September 3, 2015.

As part of the restructuring measures at medical technology company Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB), the Board of Directors has appointed business administration expert Dr. Harald Hasselmann (aged 48) as the new commercial managing director for sales and finances.

With effect from October 1, 2015 he will be a member of the management team and head the company together with Dr. Edgar Löffler, a medical physicist, who is responsible for the irradiation equipment manufacturer's technical operations.

Abel Luzuriaga, who has been managing director for sales and marketing at Eckert & Ziegler BEBIG since 2012, is leaving the company of his own accord.

Harald Hasselmann, born in Hamburg, has gained extensive experience at various international pharmaceutical companies. He was head of controlling for Europe at Bayer Pharma, managing director at Schering's Hungarian subsidiary and director of the Berlin-based biotech company metaGen. He has held various positions in large and medium-sized healthcare companies and has an excellent track record in sales, controlling and implementing restructuring measures.

"With Dr. Hasselmann we have won an ideal industry expert who will serve to substantially enhance our company's skills and capabilities, especially with regard to implementing our restructuring strategy," explains Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG SA. "I am looking forward to the new challenges at Eckert & Ziegler BEBIG. The emphasis will be on the segment's profitability and growth at an international level," added Dr. Harald Hasselmann.

The Board of Directors would like to thank Mr. Luzuriaga for his dedication and in particular for his involvement in expanding the market for tumor irradiation equipment.

[R-BgO]

Eckert & Ziegler BEBIG introduces Mick® HDR Applicators for the use with SagiNova®

Seneffe, Belgium, October 17, 2015, Eckert & Ziegler BEBIG is excited to announce the integration of the Mick® Gynecological Applicators to its portfolio, compatible with the new SagiNova® HDR afterloader.

The renowned Mick® Radio-Nuclear Applicators, including the CT compatible and MR conditional Fletcher (FSD), Henschke, Split Ring, Miami, Ring & Tandem, 2 & 3 Channel Endometrial and Segmented Vaginal Applicators are currently available for sale with the SagiNova® in the U.S. and are pending approval in Europe.

"With the addition of the Mick® Applicators, we are looking forward to presenting a broad spectrum of applicators to U.S. and international SagiNova® customers. To date, our portfolio, incorporating Mick® and Eckert & Ziegler BEBIG applicators, includes more than 20 applicators for the treatment of gynecological cancers. This enables the accurate and reliable treatment in nearly any anatomy" says William Dowd, Managing Director of Eckert & Ziegler BEBIG, Inc. and Mick Radio-Nuclear Instruments, Inc.

Besides the extensive range of gynecological applicators, Eckert & Ziegler BEBIG offers a broad spectrum of applicators accessories for treatment of prostate, breast, esophagus, bronchus, interstitial and head and neck cancers. For skin cancers, one of the most common cancers in the U.S. with nearly 5 million people treated annually, Mick® offers the unique Harrison-Anderson-Mick (H.A.M.) Applicators which have proven flexible enough to conform to and accurately treat a variety of different surface conditions.

All these applicators are also being implemented in the databases of SagiNova® and SagiPlan®. This allows for fast and accurate applicator reconstruction in the planning system and enables precise automatic length verification by the afterloader.

For more information, please visit us on booth no. 441 at this year's ASTRO Annual Meeting in San Antonio, TX (USA) or contact your local Eckert & Ziegler BEBIG representative.

[R-BgO]

Antwort auf Beitrag Nr.: 50.878.110 von R-BgO am 19.10.15 10:11:58

Eckert & Ziegler BEBIG provides the first HDR brachytherapy afterloader for Barbados

Seneffe, Belgium, February 8, 2016, Eckert & Ziegler BEBIG is proud to announce that it has provided the first High Dose Rate (HDR) afterloader for Barbados which represents an important step in the country's fight against cancer. The first gynecological patient has already begun treatment with the SagiNova® device.

"We are very happy that the Queen Elizabeth Hospital in Bridgetown decided in favour of our SagiNova® HDR afterloader and therewith introduced the first and to date only brachytherapy system to Barbados." states Kentaro Mazur, Area General Manager for Eckert & Ziegler BEBIG in Latin America. He adds that the hospital was impressed by the safety features of the device and the broad HDR applicator portfolio together with Eckert & Ziegler BEBIG`s long record of experience in HDR brachytherapy.

SagiNova® will be used initially to treat cervical cancer which ranks as the 2nd most frequent cancer and also the 2nd leading cause of cancer deaths in women aged 15 to 44 years in Barbados. The Oncology Center of the Queen Elizabeth Hospital is expecting to carry out three to four treatments a day. Additionally, they plan to introduce SagiNova® for other brachytherapy treatments such as breast, prostate and esophagus.

[R-BgO]

warum überrascht mich das nicht?:

Published: 19:08 CEST 25-04-2016 /GlobeNewswire /Source: Eckert & Ziegler BEBIG / : EZBG /ISIN: BE0003689032

Eckert & Ziegler BEBIG: Capital Increase by Contribution in Cash with Cancellation of the preferential Rights of the current Shareholders

Ecker & Ziegler BEBIG's board of directors announced its proposal to submit to the approval of the general meeting of shareholders a capital increase by way of a contribution in cash with cancellation of the preferential right of the current shareholders for an amount of EUR 5,056,168.48, of which EUR 3,560,771.10. EUR will be allocated to the share capital and EUR 1,495,397.38 as share premium.

The beneficiary of the cancellation of the preferential rights is the company under German law, Eckert & Ziegler EZAG AG, with registered office located at Robert-Rössle-Str. 10, 13125 Berlin, Germany, i.e. the controlling shareholder of the company.

In accordance with Article 598 of the Company Code, the board of directors has determined that the issue price shall amount to EUR 0.88 per new share (i.e. the average trading price of the 30 last days).

Therefore, as a result of the proposed capital increase, 5,745,646 new shares, without nominal value, will be created, as compensation for the above-mentioned contribution and the share capital of the company will be increased to bring it from EUR 10,879,026.72 to EUR 14,439,797,82. EUR

The capital increase will be on the agenda of the next extraordinary general meeting scheduled to take place on 9 June 2016 at 11.30 am at the registered office of the company (Industrial Zone C, 7180 Seneffe), right after the annual general meeting.

The board of directors will also propose to this extraordinary general meeting to resolve on (i) a reverse stock split with a ratio of ten (10) existing shares to one (1) share and (ii) the renewal the authorisation granted to the board of directors to increase the share capital of the company (authorised capital).

[Erdman]

Antwort auf Beitrag Nr.: 52.272.490 von R-BgO am 25.04.16 19:37:55

aus der Pressemitteilung - wo war Dr. Eckert?

"The Annual General Meeting also elected Dr. Harald Hasselman, who has been with the company since October 2015, to the Board of Directors. He follows Dr. Edgar Löffler, who remains a Managing Director, but is leaving the Board of Directors at his own request. "Over the past eight years, Dr. Löffler has played an instrumental role in driving the focus toward being a complete provider of brachytherapy. We would like to thank him for this, and we are pleased that he will continue to support the company on its growth course in his role as member of the management committee," said Dr. Andreas Eckert, Chairman of the Board of Directors of Eckert & Ziegler BEBIG SA."

http://www.wallstreet-online.de/nachricht/8672669-eckert-zie…

Aber Herr Eckert, der Chairman of the Board, war auf der Hauptversammlung gar nicht anwesend.

[R-BgO]

Antwort auf Beitrag Nr.: 52.584.521 von Erdman am 10.06.16 08:49:53

warst Du dort?

[Erdman]

Antwort auf Beitrag Nr.: 52.584.521 von Erdman am 10.06.16 08:49:53

und so nahm man den freien Aktionären Eigenkapitalbesitz weg

"An Extraordinary General Meeting, that followed the Annual General Meeting, decided to increase its capital by way of a contribution in cash with cancellation of the preferential right of the current shareholders for an amount of EUR 5,056,168.48, of which EUR 3,560,771.10 EUR is allocated to the share capital and EUR 1,495,397.38 as share premium. The beneficiary of the cancellation of the preferential rights is the company under German law, Eckert & Ziegler EZAG AG, i.e. the controlling shareholder of the company. "

Damit schanzte sich EZ zu 88 Cents je Aktie 5.745.646 neue Aktien der EZB zu.
Der Eigenkapitalwert der Aktien der freien Aktionäre sank dadurch von 2,21 auf 1,88 Euro.

Sowas könnte man als Expropriation der Kleinkapitalisten durch einen Grosskapitalisten bezeichnen.

Und die Verbraucherschützer? Die Börsenaufsichtsbehörden? - Sie alle bleiben untätig. Und auch der "unabhängige" Wirtschaftsprüfer sieht dies alles als politisch korrekt an.

[Erdman]

Antwort auf Beitrag Nr.: 52.584.671 von R-BgO am 10.06.16 09:04:27

... aus gut unterrichteten Quellen

Zitat von R-BgO: warst Du dort?

über den Buschfunk bzw. aus gut unterrichteten Kreisen kann man alles erfahren.

Und die Börse lebt nun mal vom Buschfunk bzw. von Gerüchten, wobei der Buschfunk die verlässlicheren Nachrichten bringt.

[Erdman]

ach noch was

Eckert & Ziegler BEBIG has been listed on the NYSE Euronext stock exchange in Brussels since April 1997 and is registered with the Financial Services and Markets Authority in Belgium ("FSMA"). The company’s performance is therefore transparent and made public in form of reports and statistics published on regular basis.

Ob diese Behörde auch das Reporting von EZB auf Konformität mit den EU Richtlinien überprüft ?

[Erdman]

Antwort auf Beitrag Nr.: 52.584.725 von Erdman am 10.06.16 09:09:11

Zitat von Erdman:

Zitat von R-BgO: warst Du dort?

über den Buschfunk bzw. aus gut unterrichteten Kreisen kann man alles erfahren.

Und die Börse lebt nun mal vom Buschfunk bzw. von Gerüchten, wobei der Buschfunk die verlässlicheren Nachrichten bringt.

Der Buschfunk gab mir inzwischen eine Tel. Nr. Der Teilnehmer der HV hat dies bestätigt.

Übrigens wird EZB vom folgenden Analysten betreut:

Geert Smet
Avenue du Port 86C
1000 Brussels
Tel: [phone]
[e-mail]
www.investisseur.be

Er ist der Einzige. Ob er auch auf der HV war?

[R-BgO]

Antwort auf Beitrag Nr.: 52.584.674 von Erdman am 10.06.16 09:04:45

sehe das etwas anders als Du:

-BEBIG ist chronisch defizitär
-BEBIG hat eine sehr windige Bilanz (von 39 Mio. EK entfallen allein 30 auf Goodwill -wie gesagt, bei chronischen Defiziten)
-der Kurs passt zur KE-Bewertung, freie Aktionäre hätten ihre Verwässerung ohne weiteres neutralisieren können:

[R-BgO]

Antwort auf Beitrag Nr.: 52.603.040 von R-BgO am 13.06.16 12:48:57

zum Halbjahr operativ 'ne schwarze Null,

netto weiter rot;


interessant:


=> die KE wurde also notwendig, weil man anscheinend anders seine Rechnungen nicht bezahlen konnte...

[R-BgO]

Eckert & Ziegler BEBIG: Eckert & Ziegler buys Belgian provider of brachytherapy accessories

Seneffe, August 26, 2016.


Eckert & Ziegler BEBIG SA took over 100 % of the shares in BrachySolutions BVBA effective August 26, 2016. The company, which is based in Leuven, Belgium, is one of the largest independent European distributors of prostate seeds. Its main markets are Benelux and Portugal. Both parties have agreed not to disclose the purchase price.

Through the takeover, Eckert & Ziegler is acquiring BrachySolutions' customer base in Benelux, the United Kingdom, and Portugal, thereby securing its strong position in Europe as a manufacturer of seeds.

"By acquiring BrachySolutions, we are further honing our strategic focus. Our strategy centers on consolidating the market, cementing our market position in Europe, and creating synergies within our portfolio of solutions," said Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and member of the Board of Directors.

"Eckert & Ziegler's Berlin-made prostate implants stand for top quality. I believe firmly that our brachytherapy customers will continue to receive the best possible products and excellent service in the future," Luk Herremans, founder and Managing Director of BrachySolutions, added.

Brachytherapy is a medical treatment method that includes placing implants containing radioisotopes directly into tumor tissue. The local radiation provided by the implants leads to the destruction of cancer cells. Permanent brachytherapy is mainly used to treat prostate cancer.

[R-BgO]

First SagiNova® HDR afterloader entered into operation in Turkey

Seneffe, Belgium, September 26, 2016, Eckert & Ziegler BEBIG announces its first SagiNova® installation in Turkey. The device was acquired by the Sante Oncology Center in Istanbul in exchange for its GyneSource afterloader which has been in use since 2008.

The Sante Oncology Center is part of the Sante Health Service, with over 30 years' experience in radiotherapy. The hospital can treat up to 150 new patients a month and aims to be a fully equipped diagnostics and oncology treatment center. "Our aspiration is to treat our patients with the latest state-of-the-art medical equipment in order to ensure effective and efficient outcomes. We have been very satisfied with our cobalt-60 GyneSource which we have used especially for treating uterine and cervical cancer. Updating to SagiNova® gives us the opportunity to expand our brachytherapy services to other body areas in the future", says Mr. Baki Temel, CEO of the Sante Oncology Center.

As with GyneSource, the new SagiNova® is equipped with a long-lasting cobalt-60 source, providing a certified 100,000 source transfer. "We found cobalt-60 to be an effective solution for our needs. Along with the integrated In-Vivo Dosimetry System, SagiNova® is a safe and sophisticated brachytherapy afterloader, especially for the treatment of gynecological cancers", adds Mr. Temel.

Sante received its SagiNova® in March. Shortly after the delivery of SagiNova®, physician and physicist trainings were carried out by the Eckert & Ziegler BEBIG Application Service and Support, enabling a seamless transition from the old to the new afterloader.

[R-BgO]

1:10 reverse split:

Press release
REGULATED INFORMATION
27 September 2016, 5:45 pm

A - implementation of the reverse stock split of the eckert & ziegler bebig sa shares and beneficiary shares


The board of directors of Eckert & Ziegler BEBIG SA has decided to implement the reverse stock split of the shares and beneficiary shares (Class A and Class B) of Eckert & Ziegler BEBIG SA, in accordance with the resolution passed by the extraordinary shareholders' meeting held on 9 June 2016, with a ratio of one new share/beneficiary share (ISIN BE0974300320) for ten existing shares/beneficiary shares (ISIN BE0003689032).

It will take effect on 10 November 2016.

The reverse stock split is in line with Eckert & Ziegler's wish to rationalise the number of shares and beneficiary shares in circulation to take account the price evolution observed over recent years, and the low level at which the price currently stands (EUR 0,75 on 27 September 2016 at 9:07).

Indeed, the transaction should amongst other things enable to limit the price volatility, since the very low unit level necessarily results in excessive volatility and to restore a more appropriate proportional relationship between the price of the share and the lump sum fees that are being applied by financial institutions for the holding, managing, transfer and sale of shares.

[Erdman]

Antwort auf Beitrag Nr.: 52.603.040 von R-BgO am 13.06.16 12:48:57

Zitat von R-BgO: sehe das etwas anders als Du:

-BEBIG ist chronisch defizitär
-BEBIG hat eine sehr windige Bilanz (von 39 Mio. EK entfallen allein 30 auf Goodwill -wie gesagt, bei chronischen Defiziten)

Stimme da zu: defizitär, der Grossaktionär steuert das, oder hat Bebig unabhängige Geschäftsführer?
windige Bilanz. sehe ich auch so. Auch hier läuft das ganz im Sinne des Grossaktionärs.

Ebenso die a.o. HV, die in wenigen Tagen stattfindet. Ob da überhaupt noch ein freier Aktionär kommt?

und noch eine Frage, gibt es einen Halbjahresbericht der Bebig; einen Q3-Bericht erwarte ich nicht, angesichts der minimalistischen IR-Arbeit.

[Erdman]

Antwort auf Beitrag Nr.: 53.635.521 von Erdman am 07.11.16 12:22:33

Die Tagesordnung zur a.o. HV findet man hier:

http://www.bebig.com/fileadmin/bebig_neu/user_uploads/IR/Gen…

http://www.bebig.com/fileadmin/bebig_neu/user_uploads/IR/Gen…

und die Angaben zur vorgeschlagenen Verschmelzung der vor kurzem gekauften neuen Firma aus Löwen findet man hier. Allerdings fehlen alle Angaben zu den wirtschaflichen Werten beider Gesellschaften.
Deshalb vermute ich, dass nach der Verschmelzung eine Goodwill-Abschreibung auf den wahrscheinlich hohen Kaufpreis erfolgt. Dann macht Bebig wohl auch in 2016 wieder einen Verlust. Angesichts der fehlenden Bereitschaft von Bebig Bilanzzahlen der zu verschmelzenden Firmen bekannt zu geben, ist eine Beurteilung dieser Transaktion unmöglich.

http://www.bebig.com/fileadmin/bebig_neu/user_uploads/IR/Gen…

[R-BgO]

mein Erinnerungsstück

wurde ausgebucht;


lasse Bebig vorläufig trotzdem in meinem Excel drin

[R-BgO]

Thread: Eckert & Ziegler Bebig - neue WKN nach reverse-split